COMMUNIQUÉS West-GlobeNewswire

CytomX Therapeutics Announces Third Quarter 2018 Financial Results
06/11/2018
ESMO Presentations Support CX-072 Product Profile and Probody™ Proof-of-Concept Advancement of Clinical Stage Probody Drug Conjugate Programs, CX-2009 and CX-2029 CX-188 IND Filing Marks Fifth Probody Therapeutic to [...]
Dova Pharmaceuticals to Present at Upcoming Investor Conferences
06/11/2018
DURHAM, N.C., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that the management team will present a company overview at four upcoming investor conferences: On Tuesday, [...]
Athersys Reports Third Quarter 2018 Results
06/11/2018
Management to host conference call at 4:30pm EST today CLEVELAND, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the period ended September 30, 2018. Highlights [...]
Aravive Reports Third Quarter 2018 Financial Results and Provides Company Updates
06/11/2018
- Merger completed; now operating as Aravive, Inc. (Nasdaq:ARAV), a clinical-stage biopharmaceutical company advancing innovative oncology therapeutics - FDA Fast Track designation granted for lead candidate, AVB-S6-500 [...]
Myriad Genetics Reports Fiscal First-Quarter 2019 Financial Results
06/11/2018
Total First-Quarter Revenues of $202.3 Million, Up 13 Percent First-Quarter Diluted EPS of ($0.01) and Adjusted EPS of $0.43, Up 48 Percent Revised Full-Year Revenue Guidance to $855 to $865 Million; Maintained Diluted [...]
Zafgen to Present at the Stifel 2018 Healthcare Conference
06/11/2018
BOSTON, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients [...]
Cutera Reports Third Quarter 2018 Financial Results
06/11/2018
truSculpt® iD Sets Company Record for New System Launch Company Achieves Sequential Gross Margin Improvement BRISBANE, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Cutera, Inc. (NASDAQ: CUTR ) (“Cutera” or the “Company”), [...]
Aptose Reports Results for the Third Quarter Ended September 30, 2018
06/11/2018
Conference call is scheduled for tomorrow, Wednesday, November 7 th at 8:00 AM ET SAN DIEGO and TORONTO, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a [...]
Paratek Pharmaceuticals Reports Third Quarter 2018 Financial Results
06/11/2018
--NUZYRA™ (omadacycline) approved by FDA for the treatment of CABP and ABSSSI -- -- SEYSARA™ (sarecycline) approved by FDA for the treatment of moderate to severe acne vulgaris -- -- Company planning for a February 2019 [...]
Aclaris Therapeutics Reports Third Quarter 2018 Financial Results and Provides Update on Clinical and Commercial Developments
06/11/2018
Management to Host Conference Call at 5:00 PM ET today WAYNE, Pa., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company focused on identifying, [...]
Principia Biopharma Reports Third Quarter Financial Results
06/11/2018
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with [...]
Immune Design Reports Third Quarter 2018 Financial Results and Provides Corporate Update
06/11/2018
Conference call at 1:30 pm Pacific today SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology [...]
Cara Therapeutics Reports Third Quarter 2018 Financial Results
06/11/2018
– Conference call today at 4:30 p.m. ET – STAMFORD, Conn., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical [...]
Allena Pharmaceuticals to Present at Upcoming Investor Conferences in November
06/11/2018
NEWTON, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to [...]
Sientra Reports Third Quarter 2018 Financial Results
06/11/2018
Achieves Total Net Sales of $16.9 Million, Pro Forma Growth of 58% YoY, 72% on a GAAP Basis Record miraDry Net Sales of $8.3 Million, Pro Forma Growth of 174% YoY, 282% on a GAAP Basis Initiates International Expansion [...]
Xenon Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
06/11/2018
Robust, Novel Pipeline of Neurology Candidates Advancing in Clinical Development Conference Call at 4:30 pm ET Today BURNABY, British Columbia, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE [...]
Iovance Biotherapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
06/11/2018
Company to Host Conference Call at 4:30pm ET Today SAN CARLOS, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies [...]
Bellicum Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
06/11/2018
HOUSTON, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today [...]
Bone Therapeutics annonce les conclusions de l'analyse intermédiaire de l'étude de phase III avec PREOB dans l’ostéonécrose de la hanche
06/11/2018
Information réglementée – Information privilégiée Le DSMB recommande l'arrêt de l'essai clinique de phase III pour futilité Programmes de développement entièrement axés sur la plateforme ALLOB et JTA-004 Gosselies, [...]

Pages